Related references
Note: Only part of the references are listed.Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial
T. C. Schneider et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer
Xiao-Yuan Chu et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Prognostic Relevance of Survivin in Pancreatic Endocrine Tumors
Sara Ekeblad et al.
WORLD JOURNAL OF SURGERY (2012)
Hesperetin, a potential therapy for carcinoid cancer
Barbara Zarebczan et al.
AMERICAN JOURNAL OF SURGERY (2011)
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway
Ruixin Liu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Expression of the Active Notch1 Decreases MTC Tumor Growth In Vivo
Renata Jaskula-Sztul et al.
JOURNAL OF SURGICAL RESEARCH (2011)
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey J. Wallin et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Disruption of the AKT Pathway Inhibits Metastasis in an Orthotopic Model of Head and Neck Squamous Cell Carcinoma
Joseph A. Knowles et al.
LARYNGOSCOPE (2011)
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
Hugo Prazeres et al.
JOURNAL OF THYROID RESEARCH (2011)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer
Herbert Chen et al.
PANCREAS (2010)
Medullary, Anaplastic, and Metastatic Cancers of the Thyroid
Susan C. Pitt et al.
SEMINARS IN ONCOLOGY (2010)
Cell cyclins: triggering elements of cancer or not?
Michael Stamatakos et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2010)
Inhibition of Phosphatidylinositol 3-Kinase/Akt Signaling Suppresses Tumor Cell Proliferation and Neuroendocrine Marker Expression in GI Carcinoid Tumors
Susan C. Pitt et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Phosphatidylinositol 3-Kinase-Akt Signaling in Pulmonary Carcinoid Cells
Susan C. Pitt et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Inhibition of the PI3K Pathway Suppresses Hormonal Secretion and Limits Growth in Pheochromocytoma Cells
Joel T. Adler et al.
WORLD JOURNAL OF SURGERY (2009)
The PI3K/Akt pathway: Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors
Craig W. Lindsley et al.
CURRENT CANCER DRUG TARGETS (2008)
Current management of medullary thyroid cancer
Rebecca S. Sippel et al.
ONCOLOGIST (2008)
The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancer
Susan C. Pitt et al.
SURGERY (2008)
Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways
Muthusamy Kunnimalaiyaan et al.
SURGERY (2007)
Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells
Muthusamy Kunnimalaiyaan et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells
Muthusamy Kunnimalaiyaan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002
Muthusamy Kunnimalaiyaan et al.
SURGERY (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Medullary thyroid cancer: the Functions of raf-1 and human achaete-scute homologue-1
H Chen et al.
THYROID (2005)
The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells
M Mandal et al.
BRITISH JOURNAL OF CANCER (2005)
Expression, purification, and inhibition of human RET tyrosine kinase
L Mologni et al.
PROTEIN EXPRESSION AND PURIFICATION (2005)
Minireview: Cyclin D1: Normal and abnormal functions
MF Fu et al.
ENDOCRINOLOGY (2004)
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells
RS Sippel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma
N Bhattacharyya
OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2003)
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells
RS Sippel et al.
SURGERY (2003)
Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway
C Segouffin-Cariou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
